A recent study featured in Volume 14 of the journal Bone Research highlights a potential hormonal treatment that could significantly alleviate chronic back pain by targeting abnormal nerve growth within injured spinal tissues. This groundbreaking research, spearheaded by Dr. Janet L. Crane from the Center for Musculoskeletal Research at Johns Hopkins University School of Medicine, sheds light on the role of bone cells in pain signaling associated with spinal degeneration.
Dr. Crane explains, "In cases of spinal degeneration, pain-sensitive nerves proliferate into areas where they typically do not exist. Our research demonstrates that parathyroid hormone (PTH) can reverse this process by activating natural signals that repel these nerves."
Exploring the Role of Parathyroid Hormone
PTH is a hormone produced by the parathyroid glands, crucial for calcium regulation and bone remodeling. While synthetic PTH is already employed in osteoporosis treatments, its potential to alleviate bone-related pain was not fully understood until now.
The research team utilized three mouse models that simulate common causes of spinal degeneration, including natural aging and genetic predispositions. Mice received daily PTH injections over periods ranging from two weeks to two months, while control groups were administered inactive solutions. The team then examined spinal tissues using advanced imaging techniques and assessed pain responses to various stimuli.
Enhanced Spinal Health and Diminished Pain Sensitivity
After treatment, mice that received PTH exhibited marked improvements in their vertebral endplates, the thin structures separating spinal discs from vertebrae, which became denser and more stable. Additionally, these mice showed a notable reduction in pain sensitivity, better tolerance to pressure, slower reactions to heat, and increased overall activity compared to untreated counterparts.
Mechanism Behind PTH's Effectiveness
Further investigation revealed that PTH treatment significantly curbed the growth of pain-sensing nerve fibers in damaged tissues. By stimulating osteoblasts to produce a protein called Slit3, PTH effectively repelled nerve fibers from entering sensitive spinal areas.
Laboratory tests confirmed that Slit3 directly inhibits nerve growth. When nerve cells were exposed to this protein, their extensions were shorter and less invasive. Conversely, removing Slit3 from osteoblasts in mice negated PTH's ability to reduce nerve growth or improve pain responses. The study also identified a regulatory protein, FoxA2, which triggers Slit3 production in response to PTH, further illuminating the hormonal signals that guide nerve behavior.
Implications for Future Treatments
Although these findings are based on animal studies, they may clarify why some patients receiving PTH for osteoporosis report less back pain. The researchers emphasize the need for further human studies to explore this innovative treatment's clinical applications.
"Our research indicates that PTH treatment for low back pain during spinal degeneration could mitigate abnormal nerve growth, paving the way for future clinical trials that assess PTH's potential as a disease-modifying and pain-relief option," concludes Dr. Crane.
About Dr. Janet L. Crane
Dr. Crane is an Associate Professor of Pediatrics at Johns Hopkins University School of Medicine, where she directs the Pediatric Bone Health Program. Her extensive research focuses on metabolic bone diseases and skeletal fragility.